DHRS13: A Protein Involved in Xenobiotic Detoxification (G147015)

Target Name: DHRS13

NCBI ID: G147015

DHRS13

DHRS13: A Protein Involved in Xenobiotic Detoxification

DHRS13 (Dehydrogenase/reductase SDR family member 13) is a protein that is expressed in various tissues throughout the body. It is a member of the SDR family, which is a group of proteins that play a critical role in the detoxification and metabolism of xenobiotics, such as drugs and other harmful substances. DHRS13 is involved in the detoxification of xenobiotics through the reduction of their hydrogen levels, which is a key step in their elimination from the body.

One of the unique features of DHRS13 is its ability to reduce xenobiotics to their elemental form, which is then excreted in the urine. This ability makes it an attractive drug target for researchers because it allows for the targeted delivery of drugs that are difficult to eliminate from the body. In addition, DHRS13 is also involved in the metabolism of xenobiotics, which can lead to the formation of toxic metabolites that can be harmful to the body.

DHRS13 is a 120-kDa protein that is expressed in various tissues, including the liver, spleen, and kidney. It is primarily localized to the endoplasmic reticulum, which is the membrane-bound system for the transport of proteins from the cytoplasm to the endoplasmic reticulum. DHRS13 is also expressed in the peribonal matrix, which is the surrounding tissue of the bone, and in the extracellular matrix, which is the tissue outside the cell.

DHRS13 is involved in the detoxification of a wide variety of xenobiotics, including drugs, pesticides, and other harmful substances. It is well established that many drugs are metabolized to inactive forms by DHRS13, and that the detoxification of these drugs is a critical step in their elimination from the body. In addition, DHRS13 is also involved in the metabolism of xenobiotics that can lead to the formation of toxic metabolites, which can be harmful to the body.

One of the unique features of DHRS13 is its ability to reduce xenobiotics to their elemental form, which is then excreted in the urine. This ability makes it an attractive drug target for researchers because it allows for the targeted delivery of drugs that are difficult to eliminate from the body. In addition, DHRS13 is also involved in the metabolism of xenobiotics, which can lead to the formation of toxic metabolites that can be harmful to the body.

DHRS13 is a 120-kDa protein that is expressed in various tissues, including the liver, spleen, and kidney. It is primarily localized to the endoplasmic reticulum, which is the membrane-bound system for the transport of proteins from the cytoplasm to the endoplasmic reticulum. DHRS13 is also expressed in the peribonal matrix, which is the surrounding tissue of the bone, and in the extracellular matrix, which is the tissue outside the cell.

In conclusion, DHRS13 is a protein that is involved in the detoxification and metabolism of xenobiotics. Its ability to reduce xenobiotics to their elemental form and its involvement in the detoxification of many drugs make it an attractive drug target for researchers. Further studies are needed to fully understand the role of DHRS13 in the detoxification and metabolism of xenobiotics.

Protein Name: Dehydrogenase/reductase 13

Functions: Putative oxidoreductase

The "DHRS13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DHRS13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets